Peptides in Oncology I: LH-RH Agonists and Antagonists
Hormonal treatment of malignant diseases has been used for quite some years now, and progress in this field is still being made at a steady pace. The detection of new endocrine feed back loops and the availability of new classes of hormonal agents made hormonal intervention with predictable outcome...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Milano
Springer Milan
1992
|
| Schriftenreihe: | Recent Results in Cancer Research
124 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Hormonal treatment of malignant diseases has been used for quite some years now, and progress in this field is still being made at a steady pace. The detection of new endocrine feed back loops and the availability of new classes of hormonal agents made hormonal intervention with predictable outcome possible. Besides the intellectual challenge of modulating the hormone system, an important aspect of recent research on hormones and cancer is the reduction of treatment-related morbidity achieved with the new hormonal strategies. Thus, controlled intervention in the hypothalamic-gonadotropic axis is increasingly apt to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. In the same way as, for example, aromatase inhibitors are being used as a substitute for adrenalectomy. The concept that secretion of hypothalamic gonadotropin releasing hormone (GnRH), pituitary gonadotropins, and sex steroids are regulated via negative and positive feedback loops is based on the pioneering work of Hohlweg and Harris some 40 years ago. In 1971, a breakthrough was achieved with the isolation, structural analysis, and synthesis of the luteinizing hormone releasing hormone (LH-RH), or GnRH as it is now more appropriately termed, since it provokes the secretion of both gonadotropins, LH and FSH, and since then the progress made in this area of research has been remarkable. Both ago nists and antagonists of LH-RH have been synthesized and extensively studied in preclinical and clinical settings |
| Beschreibung: | 1 Online-Ressource (XII, 141 p. 6 illus) |
| ISBN: | 9788847021860 |
| DOI: | 10.1007/978-88-470-2186-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046146527 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1992 |||| o||u| ||||||eng d | ||
| 020 | |a 9788847021860 |9 978-88-470-2186-0 | ||
| 024 | 7 | |a 10.1007/978-88-470-2186-0 |2 doi | |
| 035 | |a (ZDB-2-SME)978-88-470-2186-0 | ||
| 035 | |a (OCoLC)1119004675 | ||
| 035 | |a (DE-599)BVBBV046146527 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 245 | 1 | 0 | |a Peptides in Oncology I |b LH-RH Agonists and Antagonists |c edited by K. Höffken |
| 264 | 1 | |a Milano |b Springer Milan |c 1992 | |
| 300 | |a 1 Online-Ressource (XII, 141 p. 6 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Recent Results in Cancer Research |v 124 | |
| 520 | |a Hormonal treatment of malignant diseases has been used for quite some years now, and progress in this field is still being made at a steady pace. The detection of new endocrine feed back loops and the availability of new classes of hormonal agents made hormonal intervention with predictable outcome possible. Besides the intellectual challenge of modulating the hormone system, an important aspect of recent research on hormones and cancer is the reduction of treatment-related morbidity achieved with the new hormonal strategies. Thus, controlled intervention in the hypothalamic-gonadotropic axis is increasingly apt to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. In the same way as, for example, aromatase inhibitors are being used as a substitute for adrenalectomy. The concept that secretion of hypothalamic gonadotropin releasing hormone (GnRH), pituitary gonadotropins, and sex steroids are regulated via negative and positive feedback loops is based on the pioneering work of Hohlweg and Harris some 40 years ago. In 1971, a breakthrough was achieved with the isolation, structural analysis, and synthesis of the luteinizing hormone releasing hormone (LH-RH), or GnRH as it is now more appropriately termed, since it provokes the secretion of both gonadotropins, LH and FSH, and since then the progress made in this area of research has been remarkable. Both ago nists and antagonists of LH-RH have been synthesized and extensively studied in preclinical and clinical settings | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 700 | 1 | |a Höffken, K. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9788847021884 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783540552871 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9788847021877 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-88-470-2186-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031526712 | ||
| 966 | e | |u https://doi.org/10.1007/978-88-470-2186-0 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180484612161536 |
|---|---|
| any_adam_object | |
| author2 | Höffken, K. |
| author2_role | edt |
| author2_variant | k h kh |
| author_facet | Höffken, K. |
| building | Verbundindex |
| bvnumber | BV046146527 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-88-470-2186-0 (OCoLC)1119004675 (DE-599)BVBBV046146527 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-88-470-2186-0 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03015nmm a2200421zcb4500</leader><controlfield tag="001">BV046146527</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1992 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9788847021860</subfield><subfield code="9">978-88-470-2186-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-88-470-2186-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-88-470-2186-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119004675</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146527</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Peptides in Oncology I</subfield><subfield code="b">LH-RH Agonists and Antagonists</subfield><subfield code="c">edited by K. Höffken</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Milano</subfield><subfield code="b">Springer Milan</subfield><subfield code="c">1992</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XII, 141 p. 6 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Recent Results in Cancer Research</subfield><subfield code="v">124</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Hormonal treatment of malignant diseases has been used for quite some years now, and progress in this field is still being made at a steady pace. The detection of new endocrine feed back loops and the availability of new classes of hormonal agents made hormonal intervention with predictable outcome possible. Besides the intellectual challenge of modulating the hormone system, an important aspect of recent research on hormones and cancer is the reduction of treatment-related morbidity achieved with the new hormonal strategies. Thus, controlled intervention in the hypothalamic-gonadotropic axis is increasingly apt to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. In the same way as, for example, aromatase inhibitors are being used as a substitute for adrenalectomy. The concept that secretion of hypothalamic gonadotropin releasing hormone (GnRH), pituitary gonadotropins, and sex steroids are regulated via negative and positive feedback loops is based on the pioneering work of Hohlweg and Harris some 40 years ago. In 1971, a breakthrough was achieved with the isolation, structural analysis, and synthesis of the luteinizing hormone releasing hormone (LH-RH), or GnRH as it is now more appropriately termed, since it provokes the secretion of both gonadotropins, LH and FSH, and since then the progress made in this area of research has been remarkable. Both ago nists and antagonists of LH-RH have been synthesized and extensively studied in preclinical and clinical settings</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Höffken, K.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9788847021884</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783540552871</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9788847021877</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-88-470-2186-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526712</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-88-470-2186-0</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046146527 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:30Z |
| institution | BVB |
| isbn | 9788847021860 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526712 |
| oclc_num | 1119004675 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XII, 141 p. 6 illus) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1992 |
| publishDateSearch | 1992 |
| publishDateSort | 1992 |
| publisher | Springer Milan |
| record_format | marc |
| series2 | Recent Results in Cancer Research |
| spelling | Peptides in Oncology I LH-RH Agonists and Antagonists edited by K. Höffken Milano Springer Milan 1992 1 Online-Ressource (XII, 141 p. 6 illus) txt rdacontent c rdamedia cr rdacarrier Recent Results in Cancer Research 124 Hormonal treatment of malignant diseases has been used for quite some years now, and progress in this field is still being made at a steady pace. The detection of new endocrine feed back loops and the availability of new classes of hormonal agents made hormonal intervention with predictable outcome possible. Besides the intellectual challenge of modulating the hormone system, an important aspect of recent research on hormones and cancer is the reduction of treatment-related morbidity achieved with the new hormonal strategies. Thus, controlled intervention in the hypothalamic-gonadotropic axis is increasingly apt to replace surgical removal of the relevant glands, i. e. , the pituitary gland or the gonads. In the same way as, for example, aromatase inhibitors are being used as a substitute for adrenalectomy. The concept that secretion of hypothalamic gonadotropin releasing hormone (GnRH), pituitary gonadotropins, and sex steroids are regulated via negative and positive feedback loops is based on the pioneering work of Hohlweg and Harris some 40 years ago. In 1971, a breakthrough was achieved with the isolation, structural analysis, and synthesis of the luteinizing hormone releasing hormone (LH-RH), or GnRH as it is now more appropriately termed, since it provokes the secretion of both gonadotropins, LH and FSH, and since then the progress made in this area of research has been remarkable. Both ago nists and antagonists of LH-RH have been synthesized and extensively studied in preclinical and clinical settings Oncology Oncology Höffken, K. edt Erscheint auch als Druck-Ausgabe 9788847021884 Erscheint auch als Druck-Ausgabe 9783540552871 Erscheint auch als Druck-Ausgabe 9788847021877 https://doi.org/10.1007/978-88-470-2186-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Peptides in Oncology I LH-RH Agonists and Antagonists Oncology Oncology |
| title | Peptides in Oncology I LH-RH Agonists and Antagonists |
| title_auth | Peptides in Oncology I LH-RH Agonists and Antagonists |
| title_exact_search | Peptides in Oncology I LH-RH Agonists and Antagonists |
| title_full | Peptides in Oncology I LH-RH Agonists and Antagonists edited by K. Höffken |
| title_fullStr | Peptides in Oncology I LH-RH Agonists and Antagonists edited by K. Höffken |
| title_full_unstemmed | Peptides in Oncology I LH-RH Agonists and Antagonists edited by K. Höffken |
| title_short | Peptides in Oncology I |
| title_sort | peptides in oncology i lh rh agonists and antagonists |
| title_sub | LH-RH Agonists and Antagonists |
| topic | Oncology Oncology |
| topic_facet | Oncology Oncology |
| url | https://doi.org/10.1007/978-88-470-2186-0 |
| work_keys_str_mv | AT hoffkenk peptidesinoncologyilhrhagonistsandantagonists |